Pay in 4 interest-free payments of $5.41 Learn more
Ships within 48 hours · Estimated delivery Oct 8 - Oct 13
CSCs have been linked to chemoresistance in cancer patients, which accounts for 90% of treatment failures
Learn How & Apply HSN Card and QCard perks Apply online or call 1-800-695-1418
patents have a 20-year term from the filing date [2]
Weight Loss Results: In a 48-week trial with people who had obesity: 12 mg dose: Average weight loss of 24.2% 8 mg dose: Average weight loss of 17.5% Placebo: Weight loss of 2.1% Let me put that in perspective: If you weigh 250 pounds: 24.2% weight loss = 60 pounds lost And people were still losing weight when the trial ended (no plateau reached yet) How this compares to other medications: Semaglutide (Wegovy): ~15% weight loss Tirzepatide (Zepbound): ~20% weight loss Retatrutide: ~24% weight loss This is the most significant weight loss we've seen with any medication to date
This means you eat fewer total calories, which is the goal for weight management
